169. メンケス病 Disease details / Clinical trials / Drug dev / DR info

臨床試験数 : 9 / 薬物数 : 8 - (DrugBank : 3) / 標的遺伝子数 : 9 - 標的パスウェイ数 : 16

薬物、開発者（Primary Sponsor）、臨床試験情報（症例登録開始年（Enrollment year）、フェーズ、ID、実施国）
Copper
   Hamamatsu University School of Medicine
      2014   -   JPRN-UMIN000030626   Japan
   Kobe Unniversitu Graduate School of Medicine
      2011   -   JPRN-UMIN000005259   Japan
Copper histidinate
   Sentynl Therapeutics, Inc.
      2020   -   NCT04074512   United States
Copper histidine
   Cyprium Therapeutics, Inc.
      2009   Phase 3   NCT00811785   United States
   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
      1990   Phase 1/Phase 2   NCT00001262   United States
Droxidopa
   Stephen G. Kaler, MD
      2021   Phase 1/Phase 2   NCT04977388   United States
Droxidopa oral product
   Stephen G. Kaler
      2026   Phase 1/Phase 2   NCT07398508   United States
Histidine
   Hamamatsu University School of Medicine
      2014   -   JPRN-UMIN000030626   Japan
   Kobe Unniversitu Graduate School of Medicine
      2011   -   JPRN-UMIN000005259   Japan
Long term follow-UP
   Sentynl Therapeutics, Inc.
      2019   -   NCT04337684   United States
Recombinant adeno-associated virus administration
   Kunming Hope of Health Hospital
      2022   Early Phase 1   NCT05507996   China